Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Public ClinicalTrials.gov record NCT00640185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Study identification
- NCT ID
- NCT00640185
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2008
- Primary completion
- Jul 31, 2008
- Completion
- Jul 31, 2008
- Last update posted
- Jan 17, 2013
2008
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 7546 | Lafayette | California | 94549 | — |
| Site Reference ID/Investigator# 7551 | Jacksonville | Florida | 32216 | — |
| Site Reference ID/Investigator# 7553 | Orlando | Florida | 32806 | — |
| Site Reference ID/Investigator# 7545 | Overland Park | Kansas | 66212 | — |
| Site Reference ID/Investigator# 7552 | Farmington Hills | Michigan | 48336 | — |
| Site Reference ID/Investigator# 7548 | Troy | Michigan | 48085 | — |
| Site Reference ID/Investigator# 7554 | Eugene | Oregon | 97401 | — |
| Site Reference ID/Investigator# 7547 | Portland | Oregon | 97210 | — |
| Site Reference ID/Investigator# 7555 | Memphis | Tennessee | 38119 | — |
| Site Reference ID/Investigator# 7549 | Virginia Beach | Virginia | 23452 | — |
| Site Reference ID/Investigator# 7550 | Bellevue | Washington | 98007 | — |
| Site Reference ID/Investigator# 7631 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00640185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2013 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00640185 live on ClinicalTrials.gov.